ARTICLE | Company News
Arginetix, Immune Control deal
June 21, 2010 7:00 AM UTC
Arginetix and Immune Control merged to form Corridor Pharmaceuticals Inc. The newco will develop therapies for vascular diseases, initially focusing on pulmonary arterial hypertension (PAH). Corridor...